Innate Pharma S.A. Price & Performance (IPHA)

Innate Pharma has secured a €15 million investment from Sanofi, with the pharmaceutical giant subscribing to over eight million new shares at €1.7974 each. The capital infusion is designed to extend Innate’s financial runway and support ongoing clinical programs, with shares set to begin trading in Paris today.123

Despite Sanofi’s decision to end collaboration on a key leukemia drug, analysts reaffirmed a Buy rating for Innate Pharma, maintaining an $11 target price. Innate will regain full rights to the drug and continue developing other promising candidates, with the Sanofi investment seen as a strong endorsement of its core technology.45

The closing of Innate Pharma’s capital increase, backed by Sanofi’s €15 million investment, is set for today. Shares will be admitted to trading on Euronext Paris, enhancing Innate’s resources for pipeline execution and long-term growth. Analyst consensus remains positive, with significant upside projected for the stock.637